The global market for orthopedic regenerative medicine is expected to be worth USD 15.09 billion by 2028 from USD 8.78 billion in 2023, growing at a CAGR of 11.44% from 2023 to 2028.
Impact of COVID-19 on the global orthopedic regenerative medicine market:
The COVID-19 pandemic has had a significant impact on the global orthopedic regenerative medicine market as it led to the cancellations and delays of many orthopedic regenerative procedures. With restricted travel, there was a decrease in the demand for these treatments. The increased financial strain on patients due to job loss and reduced economic activity also made it difficult for them to afford regenerative treatment. As the research focus shifted towards the development of covid vaccines, it disrupted research activities and clinical trials in the regenerative medicine area, slowing down the development and approval of new regenerative therapies. Overall, the COVID-19 pandemic slowed down the market growth for orthopedic regenerative medicine, but the long-term effects remain to be seen. Since the pandemic influenced the adoption of telemedicine, it might influence the behaviour of patients towards seeking treatment which can also affect the regenerative medicine market indirectly.
MARKET DRIVERS:
The growing patient population suffering from orthopedic disorders such as osteoarthritis, joint injuries and other musculoskeletal disorders majorly propel the orthopedic regenerative medicine market growth. The development of new technologies such as 3D printing and tissue engineering is driving the growth of the orthopedic regenerative medicine market. Such advancements in technologies facilitate the creation of customized implants and tissues that can be used in regenerative procedures. The rising healthcare expenditure across the world, especially in developing countries, is contributes to the growth of the orthopedic regenerative medicine market. As research and development continue to improve healthcare systems and accessibility expands, more patients can access regenerative treatments. As people age, they are more likely to develop orthopedic disorders, therefore the growing ageing population across the globe is another factor that will drive market growth over the forecasted period due to the expected growth in demand for regenerative treatments.
MARKET RESTRAINTS:
The high cost of regenerative treatments, complex regulatory requirements, and ethical and legal issues primarily hamper the growth of the orthopedic regenerative medicine market. Regenerative medicine treatments of bones and joints can be expensive, and this can act as a major barrier for many patients to access these treatments, particularly in developing countries where healthcare expenses are a major concern. Small and medium-sized companies can face barriers in entering the industry as they might face challenges in meeting complex and stringent regulatory requirements. While a growing interest in regenerative medicine treatments is witnessed, there is still a lack of clinical evidence to support the efficacy and safety of these treatments. This can pose a challenge to gaining regulatory approval and hinder market growth. The use of stem cells in regenerative medicine treatments raises ethical and legal issues, particularly around the use of embryonic stem cells. This can limit the development and use of certain regenerative treatments.
REPORT COVERAGE:
REPORT METRIC |
DETAILS |
Market Size Available |
2022 to 2028 |
Base Year |
2022 |
Forecast Period |
2023 to 2028 |
Segments Covered |
By Treatment Type, Disease Indication, End-User and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This research report on the global orthopedic regenerative medicine market has been segmented and sub-segmented into the following categories.
Global Orthopedic Regenerative Medicine Market – By Treatment Type:
Based on treatment type, the stem cell therapy segment is expected to capture the largest share of the orthopedic regenerative medicine market during the forecast period owing to the potential of stem cell therapies to treat a variety of orthopedic disorders by regenerating multiple tissue types.
On the other hand, the platelet-rich plasma therapy (PRP) segment is estimated to showcase the highest Compound Annual Growth Rate (CAGR) during the forecast period in the global orthopedic regenerative medicine market. This is due to the increased popularity of Platelet-rich Plasma (PRP) therapy in recent years. PRP is a type of regenerative medicine that uses a patient's own blood to stimulate the healing and regeneration of tissues and is effective in treating orthopedic conditions such as osteoarthritis and tendonitis. Factors such as increasing awareness of PRP therapy, rising demand for non-invasive and low-cost treatments, and advancements in technology are expected to drive the growth of the PRP segment.
Global Orthopedic Regenerative Medicine Market – By Disease Indication:
Based on the disease indication, the osteoarticular diseases segment is expected to hold the leading share of the global market during the forecast period. Factors such as the growing aging population worldwide, increasing prevalence of degenerative joint diseases, rising awareness of regenerative treatment options to restore joint function and advances in stem cell therapies and tissue engineering for cartilage repair majorly drive the growth of the osteoarticular disease segment in the global market.
The rheumatoid arthritis segment is anticipated to capture a substantial share of the worldwide market during the forecast period owing to the growing prevalence of rheumatoid arthritis globally, increasing demand from patients for innovative treatments beyond traditional anti-inflammatory medications and the development of personalized regenerative therapies for immune modulation.
Global Orthopedic Regenerative Medicine Market – By End-User:
Based on end-user, the hospitals and clinics segment is expected to occupy the leading share of the worldwide market during the forecast period. Factors such as an increasing patient population seeking orthopedic treatments in established healthcare settings, the availability of specialized medical professionals and facilities for regenerative treatments and the integration of regenerative medicine into standard orthopedic care pathways drive the growth of the hospitals and clinics segment in the worldwide market.
The orthopedic specialty centers segment is anticipated to account for a substantial share of the global market in the coming years owing to the growing patient preference for specialized orthopedic care centers for comprehensive and targeted treatment options and increasing focus on research and development in orthopedic regenerative therapies.
Global Orthopedic Regenerative Medicine Market – By Region:
North America is currently holding the dominant position in the global market of orthopedic regenerative medicine because of the growing prevalence of orthopedic disorders, advanced healthcare infrastructure, and favourable reimbursement policies. While regions such as North America and Europe are expected to continue to grow, the Asia-Pacific region is expected to see the fastest growth in the coming years. This is due to various factors including the increasing healthcare expenditure, growing awareness of regenerative medicine, and growing orthopedic disorders, which are expected to drive the growth of the orthopedic regenerative medicine market in the Asia-Pacific region. In addition, the Governments of different nations in the region are taking steps to encourage the development and adoption of regenerative medicine technologies, which is expected to further fuel market growth.
KEY MARKET PLAYERS:
Companies playing a noteworthy role in the global orthopedic regenerative medicine market are Anika Therapeutics, Arthrex, Inc., Baxter International, CONMED Corporation, Johnson and Johnson, Medtronic plc, Smith and Nephew plc., Stryker Corporation, Zimmer Biomet Holdings, Inc., Vericel Corporation, AlloSource, Amniox Medical, Inc., VSY Biotechnology, Aptissen S.A. and MiMedx.
RECENT HAPPENINGS IN THE MARKET:
Frequently Asked Questions
The global orthopedic regenerative medicine market is anticipated to be worth USD 7.88 billion in 2023.
The growing aging population worldwide, increasing prevalence of orthopedic conditions, advancements in regenerative therapies, and a shift towards minimally invasive treatments primarily drive the growth of the orthopedic regenerative medicine market.
North America and Europe are witnessing significant growth due to their established healthcare infrastructure and increasing adoption of innovative treatment options.
Stringent regulations, high treatment costs, limited insurance coverage, and the need for long-term clinical evidence primarily hinder the growth of the orthopedic regenerative medicine market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region